An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

NCT01803867 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: rHIgM22

Sponsor

Acorda Therapeutics

Collaborators

[object Object]